Alkystis Phinikaridou1,2, Sara Lacerda1,2, Begoña Lavin1,2, Marcelo E Andia1,3, Alberto Smith4, Prakash Saha4, René M Botnar1,2,5,6. 1. School of Biomedical Engineering Imaging Sciences, King's College London, London, UK. 2. BHF Centre of Excellence, Cardiovascular Division, King's College London, London, UK. 3. Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, London, UK. 5. Wellcome Trust and EPSRC Medical Engineering Center, King's College London, UK. 6. Pontificia Universidad Católica de Chile, Escuela de Ingeniería, Santiago, Chile.
Abstract
Background: Elastolysis and ineffective elastogenesis favor the accumulation of tropoelastin, rather than cross-linked elastin, in atherosclerotic plaques. We developed gadolinium-labeled tropoelastin-specific magnetic resonance contrast agents (Gd-TESMAs) for tropoelastin imaging in animal models. Methods and Results: Two peptides, VVGSPSAQDEASPLS and YPDHVQYTHY were selected to target tropoelastin. In vitro binding, relaxivity, and biodistribution experiments enabled characterization of the probes and selecting the best candidate for in vivo MRI. MRI was performed in atherosclerotic apolipoprotein E-deficient (ApoE-/-) mice and New Zealand white rabbits with stable and rupture-prone plaques using Gd-TESMA. Additionally, human carotid endarterectomy specimens were imaged ex vivo. The VVGSPSAQDEASPLS-based probe discriminated between tropoelastin and cross-linked elastin (64±7% vs 1±2%, P=0.001), had high in vitro relaxivity in solution (r1-free=11.7±0.6mM-1s-1, r1-bound to tropoelastin = 44±1mM-1s-1) and favorable pharmacokinetics. In vivo mice vascular enhancement (4wks=0.13±0.007mm2, 8wks=0.22±0.01mm2, 12wks=0.33±0.01mm2, P<0.001) and R1 relaxation rate (4wks=0.90±0.01 s-1, 8wks=1.40±0.03 s-1, 12wks=1.87±0.04s-1, P<0.001) increased with atherosclerosis progression after Gd-TESMA injection. Conversely, statin-treated (0.13±0.01mm2, R1 =1.37±0.03s-1) and control (0.10±0.005mm2, R1 =0.87±0.05s-1) mice showed less enhancement. Rupture-prone rabbit plaques had higher R1 relaxation rate compared with stale plaques (R1=2.26±0.1s-1vs R1=1.43±0.02s-1, P=0.001), after administration of Gd-TESMA that allowed detection of rupture-prone plaques with high sensitivity (84.4%) and specificity (92.3%). Increased vascular R1 relaxation rate was observed in carotid endarterectomy plaques after soaking (R1pre= 1.1±0.26 s-1 vs R1post= 3.0±0.1s-1, P=0.01). Ex vivo analyses confirmed the MRI findings and showed uptake of the contrast agent to be specific for tropoelastin. Conclusions: MRI of tropoelastin provides a novel biomarker for atherosclerotic plaque progression and instability.
Background: Elastolysis and ineffective elastogenesis favor the accumulation of tropoelastin, rather than cross-linked elastin, in atherosclerotic plaques. We developed gadolinium-labeled tropoelastin-specific magnetic resonance contrast agents (Gd-TESMAs) for tropoelastin imaging in animal models. Methods and Results: Two peptides, VVGSPSAQDEASPLS and YPDHVQYTHY were selected to target tropoelastin. In vitro binding, relaxivity, and biodistribution experiments enabled characterization of the probes and selecting the best candidate for in vivo MRI. MRI was performed in atherosclerotic apolipoprotein E-deficient (ApoE-/-) mice and New Zealand white rabbits with stable and rupture-prone plaques using Gd-TESMA. Additionally, human carotid endarterectomy specimens were imaged ex vivo. The VVGSPSAQDEASPLS-based probe discriminated between tropoelastin and cross-linked elastin (64±7% vs 1±2%, P=0.001), had high in vitro relaxivity in solution (r1-free=11.7±0.6mM-1s-1, r1-bound to tropoelastin = 44±1mM-1s-1) and favorable pharmacokinetics. In vivo mice vascular enhancement (4wks=0.13±0.007mm2, 8wks=0.22±0.01mm2, 12wks=0.33±0.01mm2, P<0.001) and R1 relaxation rate (4wks=0.90±0.01 s-1, 8wks=1.40±0.03 s-1, 12wks=1.87±0.04s-1, P<0.001) increased with atherosclerosis progression after Gd-TESMA injection. Conversely, statin-treated (0.13±0.01mm2, R1 =1.37±0.03s-1) and control (0.10±0.005mm2, R1 =0.87±0.05s-1) mice showed less enhancement. Rupture-prone rabbit plaques had higher R1 relaxation rate compared with stale plaques (R1=2.26±0.1s-1vs R1=1.43±0.02s-1, P=0.001), after administration of Gd-TESMA that allowed detection of rupture-prone plaques with high sensitivity (84.4%) and specificity (92.3%). Increased vascular R1 relaxation rate was observed in carotid endarterectomy plaques after soaking (R1pre= 1.1±0.26 s-1 vs R1post= 3.0±0.1s-1, P=0.01). Ex vivo analyses confirmed the MRI findings and showed uptake of the contrast agent to be specific for tropoelastin. Conclusions: MRI of tropoelastin provides a novel biomarker for atherosclerotic plaque progression and instability.
Authors: C Rodríguez; J F Alcudia; J Martínez-González; B Raposo; M A Navarro; L Badimon Journal: Atherosclerosis Date: 2007-08-01 Impact factor: 5.162
Authors: Marcus R Makowski; Andrea J Wiethoff; Ulrike Blume; Friederike Cuello; Alice Warley; Christian H P Jansen; Eike Nagel; Reza Razavi; David C Onthank; Richard R Cesati; Michael S Marber; Tobias Schaeffter; Alberto Smith; Simon P Robinson; René M Botnar Journal: Nat Med Date: 2011-02-20 Impact factor: 53.440
Authors: R H Gandhi; E Irizarry; J O Cantor; S Keller; G B Nackman; V J Halpern; K M Newman; M D Tilson Journal: Surgery Date: 1994-05 Impact factor: 3.982
Authors: Andrea Protti; Begoña Lavin; Xuebin Dong; Silvia Lorrio; Simon Robinson; David Onthank; Ajay M Shah; Rene M Botnar Journal: J Am Heart Assoc Date: 2015-08-13 Impact factor: 5.501
Authors: Tobias Becher; Dario F Riascos-Bernal; Daniel J Kramer; Vanessa M Almonte; Jingy Chi; Tao Tong; Gustavo H Oliveira-Paula; Issam Koleilat; Wei Chen; Paul Cohen; Nicholas E S Sibinga Journal: Circ Res Date: 2020-01-09 Impact factor: 17.367
Authors: Begoña Lavin; Sara Lacerda; Marcelo E Andia; Silvia Lorrio; Robert Bakewell; Alberto Smith; Imran Rashid; René M Botnar; Alkystis Phinikaridou Journal: Cardiovasc Res Date: 2020-04-01 Impact factor: 10.787
Authors: Jazmin Ozsvar; Chengeng Yang; Stuart A Cain; Clair Baldock; Anna Tarakanova; Anthony S Weiss Journal: Front Bioeng Biotechnol Date: 2021-02-25